ストックスクリーナーアプリを入手
32.88
3.30%
1.05
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
This LB Pharmaceuticals analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN
Jennison Associates LLC Acquires 82,812 Shares of LB Pharmaceuticals Inc $LBRX - MarketBeat
LBRX LB Pharmaceuticals posts slightly smaller Q4 2025 loss than analyst estimates, shares rise 3.66 percent.Strategic Review - Newser
LBRX News Today | Why did LB Pharmaceuticals stock go down today? - MarketBeat
Equities Analysts Offer Predictions for LBRX Q1 Earnings - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Trading 5.6% HigherTime to Buy? - MarketBeat
This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright & Co. initiates coverage of LB Pharmaceuticals (LBRX) with buy recommendation - MSN
Biopharma breaks its lengthy IPO drought - MSN
Analysts Offer Insights on Healthcare Companies: LB Pharmaceuticals, Inc. (LBRX) and West Pharmaceutical Services (WST) - The Globe and Mail
[ARS] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
Executive pay, board elections lead LB Pharmaceuticals (LBRX) 2026 proxy - Stock Titan
LB Pharmaceuticals (LBRX) Business Model Review | LB Pharmaceuticals Beats EPS Estimates With Narrower LossRecovery Stocks - Cổng thông tin điện tử Tỉnh Sơn La
LBRX (LB Pharmaceuticals Inc) shares jump 9.6% after Q4 2025 EPS edges past consensus analyst estimates. - Xã Thanh Hà
LB Pharmaceuticals publishes phase 2 schizophrenia trial results By Investing.com - Investing.com India
Neuropsychiatric drug developer LB Pharma files for U.S. IPO - MSN
LBRX (LB Pharmaceuticals Inc) reports narrow Q4 2025 EPS beat but shares fall 2.88 percent in today’s trading.Trending Momentum Stocks - UBND thành phố Hải Phòng
LB Pharmaceuticals publishes phase 2 schizophrenia trial results - Investing.com
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia - ChartMill
LB Pharmaceuticals Inc Common Stock (LBRX) Competitors - Meyka
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know - TipRanks
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 4.5%Should You Sell? - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Reaches New 1-Year HighShould You Buy? - MarketBeat
[EFFECT] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
LB Pharmaceuticals (NASDAQ: LBRX) files resale prospectus for 4.78M shares - Stock Titan
Craig Hallum Initiates Coverage on LB Pharmaceuticals (NASDAQ:LBRX) - Defense World
LBRX Upgraded to Buy by Craig-Hallum on April 10, 2026 - Meyka
Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating - Investing.com UK
Craig-Hallum initiates LB Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com South Africa
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Craig Hallum - MarketBeat
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference - Bitget
Is LB Pharmaceuticals (LBRX) Stock Overpriced Now | Price at $25.67, Down 1.19%Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai
LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 6.1%Here's What Happened - MarketBeat
Investors to resell 4.78M LB Pharmaceuticals (Nasdaq: LBRX) shares - Stock Titan
Is LB Pharmaceuticals (LBRX) Stock Consolidating | Price at $25.44, Down 0.97%Quote Data - Newser
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):